Indole carboxylic acids as thyroid receptor ligands

A compound of the formula

• or the pharmaceutically acceptable salt thereof;
• wherein
• W is oxygen, CH2, CF2, NR12, S(O)m wherein m is 0, 1 or 2;
• R1, R2, and R3 are each independently selected from the group consisting of hydrogen, halo, cyano, trifluoromethyl, trifluomethoxy and (C1-C6)alkyl;
• R4 is hydrogen, halo, cyano, (C1-C12)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C6)alkyl, —OR9, —S(O)2NR10R11, —C(O)NR10R11, —C(O)R10, —CH(OH)R10, —NR12C(O)R10, —NR12C(O)NR10R11, —NR12S(O)2R10 or —S(O)nR10 wherein n is 0, 1 or 2;
• R5 is hydroxy, or, (C1-C4)alkoxy;
• R6 is hydrogen, —C(O)CH3, (C1-C6)alkyl, or phenyl(C1-C6)alkyl;
• R7 is hydrogen or (C1-C6)alkyl;
• R8 is OR12 or NR9R12;
• R9 for each occurrence is independently hydrogen, (C1-C12)alkyl, (C3-C10)cycloalkyl;
• R10 for each occurrence is independently hydrogen, (C1-C12)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, (C3-C10)cycloalkyl, (C3-C9)cycloalkyl(C1-C6)alkyl;
• R11 for each occurrence is independently hydrogen, (C1-C6)alkyl, (C3-C10) cycloalkyl or (C3-C9)cycloalkyl(C1-C6)alkyl;
• R12 for each occurrence is independently hydrogen or (C1-C6)alkyl;
• and
• R13 is hydrogen, halo or (C1-C6)alkyl.